Device Trial Radar · NCT03073265
Apixaban Validation Study - Additional Study on Fresh Samples
Last checked: Nov 20, 2026Latest source record: Mar 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
May 8, 2017
Primary completion
Nov 1, 2017
Study completion Nov 1, 2017
Sponsor
- Lead sponsor
- Diagnostica StagoNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 8, 2017
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to demonstrate the performances of STA® - Apixaban Calibrator \& STA® - Apixaban Control used in combination with STA® - Liquid Anti-Xa to measure apixaban concentration in plasma. Anti-Xa results will be compared to LCMS (liquid chromatography - mass spectrometry) for validation of the assay. For this study, the anti-Xa assay will be performed on fresh samples only. The results will be used to complete results obtained previously on frozen samples.
Conditions
- Anticoagulation With Apixaban
Interventions
STA-Apixaban Calibrator & ControlDevice
Measurement of apixaban level will be done using anti-Xa assay (IVD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Method comparison between Anti-Xa method and LCMS to measure apixaban in plasmaTime frame: The anti-Xa assay will be tested within 6h after sample collection and LCMS will be performed on frozen samples, at maximum 2 months after collection.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Moses Cone Memorial Hospital
Greensboro, North Carolina
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.